← Russell 3000 cross-section

AVXL ANAVEX LIFE SCIENCES CORP.

Trailing twelve months to 2025-12-31 · as filed 2026-02-09, not restated
Healthcare

Scale

Market cap
$297m
Revenue TTM
$4m
Net income TTM
$-40m
Free cash flow
Composite score
Sector rank
#2664

Valuation

P / E
EV / EBITDA
EV / sales
37.9
FCF yield
Earnings yield vs 10-yr
-18.16pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-915.6%
EBITDA margin
ROE
-31.6%
ROIC
Revenue growth
-34.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The decrease in research and development expenses during the three-month period is primarily related to the following: The following table summarizes our research and development expenses for the three-months ended December 31, 2025 and 2024 (in thousands): During the three-months ended December 31, 2025 and 2024, external service provider costs by product candidate was as follows (in thousands): General and administrative expenses were $2.1 million for the three months ended December 31, 2025, as compared to $3.1 million for the same quarter of fiscal 2024. …ANAVEX LIFE SCIENCES CORP., 10-Q, period ended 2025-12-31, filed 2026-02-09

Read the full passage →